News and Trends 22 Jun 2018 Radiotherapy-Enhancing Cancer Nanomedicine Secures Good Phase II/III Results A nanomedicine designed to help amplify and focus radiation treatment on hard to treat soft tissue sarcoma cells has achieved positive Phase II/III trial results for French-American biotech Nanobiotix. “Data are exceptional and show without any doubt an improvement of radiation therapy impact,” commented Sylvie Bonvalot, Head of Sarcoma and Complex Tumor Surgery Unit at […] June 22, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2018 Next-Generation CAR-T Company Raises €130M on NASDAQ IPO London-based Autolus has made its debut on the NASDAQ raising funds to boost the development of a next generation of CAR-T cell therapy for cancer. Founded in 2014 as a spin-out from University College London, Autolus has been taking great strides to develop its CAR-T technology. In less than four years, the company managed to raise nearly €150M […] June 22, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2018 Massive Series B Funding Could Bring Belgian Immuno-oncology Treatments Into the Clinic iTeos Therapeutics raised €65M ($75M) to bring two of its cancer treatments into the clinic within the next one and a half years. iTeos Therapeutics, a Belgian biotech, raised what may have been the largest Series B financing round in Europe so far this year, led by MPM Capital. The funding will be used to […] June 20, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Interview 13 Jun 2018 CAR-T Brings Hope for Cancer Patients, But Challenges Lie Ahead CAR-T cell therapy has been able to effectively treat cancer in some patients for whom all other treatment options were exhausted. However, the technology still has a long road ahead before becoming a widespread treatment option. Philip spoke to Christian Homsy, CEO of Celyad, at our Refresh Meetup in Brussels about the challenges CAR-T cell […] June 13, 2018 - 5 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jun 2018 Best of European Biotech at ASCO 2018 Not able to attend the biggest cancer conference of the year? No problem. We have summarized what we think are the most interesting therapy developments presented by European biotech’s at ASCO this year. Once again, the cream of the cancer specialist crop gathered in Chicago to discuss and present the latest findings in cancer research at […] June 6, 2018 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 28 May 2018 Genmab and Janssen Suffer Combination Therapy Setback Janssen will discontinue a Phase I study testing Danish biotech Genmab’s blood cancer blockbuster daratumumab combined with a candidate checkpoint inhibitor in patients with multiple myeloma. Janssen, which obtained the exclusive global rights to commercialize daratumumab from Genmab in 2012, will also discontinue a Phase Ib/II study of daratumumab in patients with non-small cell lung […] May 28, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 25 May 2018 Norwegian Pancreatic Cancer Vaccine Drastically Improves Survival Targovax has obtained positive Phase I/II results showing its pancreatic cancer vaccine improved the survival of 32 patients also receiving chemotherapy over two years. Targovax, based in Oslo, Norway, has obtained positive Phase I/II results confirming the efficacy of its pancreatic cancer vaccine in a larger patient population and over a longer time period than […] May 25, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 22 May 2018 Celgene Partners With German Biotech to Develop Oncology Treatments Evotec has entered into a collaboration with Celgene to identify new therapeutics in oncology with a focus on solid tumors. Evotec, based in Hamburg, has received an upfront payment of $65M (€55M) from US-based Celgene, one of the largest biotechs worldwide. The funding will be used to identify potential new cancer treatments with a focus on […] May 22, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Interview 21 May 2018 Engineering Red Blood Cells to Fight the Most Severe Cancers Our very own red blood cells could soon become a treatment for some of the most severe forms of cancer; After a long journey of ups and downs, Erytech is now near the finish line to launch the first red blood cell therapy. How amazing would it be if we could use our own cells […] May 21, 2018 - 6 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 15 May 2018 An Epigenetic Drug for Prostate Cancer Gets $26M to Enter Clinical Trials CellCentric has raised a private round to fund the development of a first-in-class drug with potential to tackle treatment-resistant prostate cancer. Cambridge-based CellCentric has raised $26M from Morningside Venture Investments. The company plans to use the cash to fund the development of an epigenetic cancer drug up to Phase 2b trials. The drug in question, called CCS1477, […] May 15, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 May 2018 German Biotech Expands Oncology Deal with Bluebird bio to $1.5Bn Medigene and bluebird bio are increasing the number of cancer targets against which to develop TCR candidates, raising their already huge deal to a massive $1.5Bn. In September 2016, Medigene and bluebird bio partnered to develop T cell receptor-modified T cells (TCR-Ts) as candidates for cancer immunotherapy treatments. Medigene was offered up to $250M per each of […] May 14, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 May 2018 Scottish Biotech Boosts its CAR-T Pipeline for Cancer and HIV TC Biopharm has partnered with Scotia Biologics to produce tumor-specific antibodies for a new generation of safer CAR-T therapies against multiple types of tumors as well as viral infections such as HIV. The Scottish biotech TC Biopharm will be working with its new partner Scotia Biologics on the development of CAR-T therapy candidates against neuroblastoma, […] May 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email